Global Juvenile Macular Degeneration Clinical Trials Review 2024, Featuring Lin Bioscience, Nanoscope Therapeutics, Alnylam Pharmaceuticals, Biophytis, Kubota Pharmaceutical and Nucleus Network
May 27, 2024 05:00 ET
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Juvenile Macular Degeneration (Stargardt Disease) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's...
Global Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials Review 2024
May 27, 2024 02:49 ET
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Wet (Neovascular / Exudative) Macular Degeneration - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's...
Global Nonmydriatic Handheld Fundus Cameras Strategic Research Report 2024: Market to Reach $259 Million by 2030 - Glaucoma Prevalence and Need for Screening to Fuel Sales
May 23, 2024 11:08 ET
|
Research and Markets
Dublin, May 23, 2024 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Nonmydriatic...
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
May 21, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support...
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
May 20, 2024 07:00 ET
|
Ocugen
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
May 15, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen to Present at May 2024 Investor Conferences
May 10, 2024 07:45 ET
|
Ocugen
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 16:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host Webcast...
Corza Medical Named “Best Overall MedTech Company” in 8th Annual MedTech Breakthrough Awards Program
May 09, 2024 10:30 ET
|
Corza Medical Inc.
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies WESTWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corza Medical...
Global Cell and Gene Therapy in Ophthalmology Research Report 2024: Market Anticipated to Soar with Projected CAGR Growth of 50.8% by 2029
May 09, 2024 09:43 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapies in Ophthalmology" report has been added to ResearchAndMarkets.com's offering.Despite the high cost of therapies, linked to the...